Pfizer Bags Positive CHMP Recommendation for LORVIQUA

Pfizer Bags Positive CHMP Recommendation for LORVIQUA

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended Pfizer Inc.’s (PFE) tyrosine kinase inhibitor (TKI) therapy, LORVIQUA, (lorlatinib, available in the U.S. under the brand name LORBRENA) for marketing authorization.  

Notably, the European Commission (EC) will now verify the CHMP’s opinion, and the company expects the decision to come up in the next few months.

LORVIQUA, a tyrosine kinase inhibitor (TKI) therapy, is designed as a first-line treatment for adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).